Virginia legislation · 2026 Regular Session
Virginia SB278: An Act to direct the Secretary of Health and Human Resources to convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth; report.
Status: Chaptered, April 13, 2026
Drug manufacturers; 340B Drug Pricing Program; work group; report. Directs the Secretary of Health and Human Resources to convene a work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth, with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved areas. The bill requires the work group to submit a report on its findings and recommendations to the Chairs of the Senate Committees on Finance and Appropriations and Education and Health and the House Committees on Appropriations and Health and Human Services by November 1, 2026.
What the bill says
An Act to direct the Secretary of Health and Human Resources to convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth; report. [S 278] Approved April 13, 2026 1. § 1. That the Secretary of Health and Human Resources (the Secretary), in consultation with the Department of Health Professions, the Board of Pharmacy, and the Department of Medical Assistance Services, shall convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program with.
From the enrolled text, April 13, 2026:
An Act to direct the Secretary of Health and Human Resources to convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth; report. [S 278] Approved April 13, 2026 1. § 1. That the Secretary of Health and Human Resources (the Secretary), in consultation with the Department of Health Professions, the Board of Pharmacy, and the Department of Medical Assistance Services, shall convene a stakeholder work group to conduct a comprehensive evaluation of the impacts of the federal 340B Drug Pricing Program within the Commonwealth with emphasis on governance, transparency, and the availability of pharmacy services in rural and underserved communities. The work group shall include representatives from the Virginia Community Healthcare Association, the Virginia Hospital and Healthcare Association, the Virginia Society of Health-System Pharmacists, the Virginia Community Pharmacy Association, Federally Qualified Health Centers (FQHCs), Pharmaceutical Research and Manufacturers of America, the Virginia Biotechnology Association, the Virginia Association of Health Plans, the Virginia Association of Chain Drug Stores, the Virginia Pharmacists Association, and other stakeholders with relevant expertise in the administration, oversight, or compliance requirements of the federal 340B Drug Pricing Program. § 2. In conducting the evaluation, the work group shall review the 2. The number and location of covered entities as defined by the Public …